-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since February, a large number of pharmaceutical companies have disclosed their 2021 performance
.
Among them, more than 240 domestic pharmaceutical companies have released performance forecasts, and the world's major multinational pharmaceutical companies, including AstraZeneca, Roche, Merck, Sanofi, Novartis, Eli Lilly, etc.
, have also released financial report information
.
On the whole, whether it is a local pharmaceutical company or a multinational pharmaceutical company, the performance in 2021 will be relatively bright
.
The author has noticed that among the local pharmaceutical companies, there is another biopharmaceutical company with a revenue exceeding 30 billion yuan and a profit exceeding 10 billion yuan, and its revenue has exceeded that of Roche, Merck &
Co.
Judging from the 2021 performance forecast disclosed by domestic pharmaceutical companies, Zhifei Bio has performed particularly well
.
On February 8, 2022, the performance report disclosed by Zhifei Biology showed that in 2021, the company's operating income was 30.
637 billion yuan, a year-on-year increase of 101.
68%; net profit was 10.
197 billion yuan, a year-on-year increase of 208.
88%
.
According to the business situation of the Chinese market disclosed by foreign pharmaceutical companies in 2021, AstraZeneca’s revenue in 2021 will be high, reaching US$6.
011 billion, followed by Roche and Merck, with revenue in the Chinese market exceeding US$4 billion, Sanofi, Novartis, Novo Nordisk, Eli Lilly and other Chinese market business are also more than 1 billion US dollars
.
Through data comparison, Zhifei Bio's revenue in 2021 has completely surpassed Roche, Merck, Sanofi, Novartis, Novo Nordisk, Eli Lilly, etc.
, and it is second to AstraZeneca
.
Regarding the reasons for the sharp increase in performance in 2021, Zhifei Bio said that during the reporting period, the sales of the company's own products and agency products continued to increase steadily, and the company's main business income, net profit and other important financial indicators were higher than the same period last year.
magnitude increase
.
According to the data, Zhifei Bio is a biopharmaceutical enterprise integrating vaccine and biological product research and development, production, sales, promotion, distribution and import and export.
Its products are mainly distributed in three categories: bacterial vaccines, virus vaccines and tuberculosis prevention and treatment.
field
.
It is understood that in the past, Zhifei Bio used agent products as its performance pillar.
In recent years, with the increase of the company's R&D investment, the development of independent products has become the main reason for the rapid increase in Zhifei Bio's performance. .
In 2021, Zhifei Bio's independent products will contribute a lot to the growth of its net profit
.
In the first half of 2021, the company's independent product revenue was 6.
037 billion yuan, a year-on-year increase of 1474.
67%, accounting for 45.
85% of revenue and 68.
33% of profit, with a gross profit margin of 86.
88%
.
Zhifei Bio disclosed in its 2020 annual report that the company signed a cooperative research and development agreement with the Institute of Microbiology, Chinese Academy of Sciences, and the co-developed recombinant new crown vaccine (CHO cells) started clinical trials in June 2020, and obtained Phase I and II clinical trials in October.
Key safety and immunogenicity data, included for emergency use in March 2021
.
On the evening of March 2, 2022, the company stated that the product has been approved by the State Food and Drug Administration for listing with conditions
.
In this regard, the company will continue to do a good job in the quality and quantity production and supply of the vaccine product
.
If the follow-up work progresses smoothly, it will promote the WHO certification of the vaccine and its sequential (heterologous) strengthening of immunization, and will also have a certain positive impact on the company's future performance, research and development progress, and internationalization strategy.
.
On March 2, Zhifei Biological closed at 124.
68 yuan, down 1.
90%, with a turnover rate of 0.
67%, a dynamic price-earnings ratio of 21.
62, and a total market value of 199.
5 billion yuan
.
On March 3, Zhifei Biological opened its quotation at 129.
45 yuan, up more than 3%.
As of 11:10, the price-earnings ratio was 21.
78, and the total market value was 200.
9 billion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, more than 240 domestic pharmaceutical companies have released performance forecasts, and the world's major multinational pharmaceutical companies, including AstraZeneca, Roche, Merck, Sanofi, Novartis, Eli Lilly, etc.
, have also released financial report information
.
On the whole, whether it is a local pharmaceutical company or a multinational pharmaceutical company, the performance in 2021 will be relatively bright
.
The author has noticed that among the local pharmaceutical companies, there is another biopharmaceutical company with a revenue exceeding 30 billion yuan and a profit exceeding 10 billion yuan, and its revenue has exceeded that of Roche, Merck &
Co.
Judging from the 2021 performance forecast disclosed by domestic pharmaceutical companies, Zhifei Bio has performed particularly well
.
On February 8, 2022, the performance report disclosed by Zhifei Biology showed that in 2021, the company's operating income was 30.
637 billion yuan, a year-on-year increase of 101.
68%; net profit was 10.
197 billion yuan, a year-on-year increase of 208.
88%
.
According to the business situation of the Chinese market disclosed by foreign pharmaceutical companies in 2021, AstraZeneca’s revenue in 2021 will be high, reaching US$6.
011 billion, followed by Roche and Merck, with revenue in the Chinese market exceeding US$4 billion, Sanofi, Novartis, Novo Nordisk, Eli Lilly and other Chinese market business are also more than 1 billion US dollars
.
Through data comparison, Zhifei Bio's revenue in 2021 has completely surpassed Roche, Merck, Sanofi, Novartis, Novo Nordisk, Eli Lilly, etc.
, and it is second to AstraZeneca
.
Regarding the reasons for the sharp increase in performance in 2021, Zhifei Bio said that during the reporting period, the sales of the company's own products and agency products continued to increase steadily, and the company's main business income, net profit and other important financial indicators were higher than the same period last year.
magnitude increase
.
According to the data, Zhifei Bio is a biopharmaceutical enterprise integrating vaccine and biological product research and development, production, sales, promotion, distribution and import and export.
Its products are mainly distributed in three categories: bacterial vaccines, virus vaccines and tuberculosis prevention and treatment.
field
.
It is understood that in the past, Zhifei Bio used agent products as its performance pillar.
In recent years, with the increase of the company's R&D investment, the development of independent products has become the main reason for the rapid increase in Zhifei Bio's performance. .
In 2021, Zhifei Bio's independent products will contribute a lot to the growth of its net profit
.
In the first half of 2021, the company's independent product revenue was 6.
037 billion yuan, a year-on-year increase of 1474.
67%, accounting for 45.
85% of revenue and 68.
33% of profit, with a gross profit margin of 86.
88%
.
Zhifei Bio disclosed in its 2020 annual report that the company signed a cooperative research and development agreement with the Institute of Microbiology, Chinese Academy of Sciences, and the co-developed recombinant new crown vaccine (CHO cells) started clinical trials in June 2020, and obtained Phase I and II clinical trials in October.
Key safety and immunogenicity data, included for emergency use in March 2021
.
On the evening of March 2, 2022, the company stated that the product has been approved by the State Food and Drug Administration for listing with conditions
.
In this regard, the company will continue to do a good job in the quality and quantity production and supply of the vaccine product
.
If the follow-up work progresses smoothly, it will promote the WHO certification of the vaccine and its sequential (heterologous) strengthening of immunization, and will also have a certain positive impact on the company's future performance, research and development progress, and internationalization strategy.
.
On March 2, Zhifei Biological closed at 124.
68 yuan, down 1.
90%, with a turnover rate of 0.
67%, a dynamic price-earnings ratio of 21.
62, and a total market value of 199.
5 billion yuan
.
On March 3, Zhifei Biological opened its quotation at 129.
45 yuan, up more than 3%.
As of 11:10, the price-earnings ratio was 21.
78, and the total market value was 200.
9 billion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
